Integrated Diagnostics Holdings Plc · LSE:IDHC
Integrated Diagnostics — FY2021 Earnings Presentation
16 slides from Integrated Diagnostics's earnings presentation, April 2022
Slide 1: IDH Results Call Presentation
IDH Results Call Presentation April 2022
Slide 2: A Record-breaking Year Across the Board
A Record-breaking Year Across the Board Record-breaking net sales of EGP 5 billion in line with guidance… IDH served a record number of patients in 2021… (Revenue | EGP mn) (Patients Served | mn) CAGR: 26% CAGR: 10% 5,048 10.3 7.0 7.5 7.1 5.8 5.8 6.4 2,656 1,921 2,226 1,514 1,015 1,171 2015 2016 201
Slide 3: A Record-breaking Year
A Record-breaking Year IDH reported an outstanding set of results in 2021 on the back of strong demand across its entire portfolio EGP 5.2 bn EGP 5.0 bn EGP 1.5 bn Revenue Net Sales Net Profit +97% y-o-y +90% y-o-y +145% y-o-y, NPM* 30% 10.3 mn 33.7 mn 502 Patients Tests Branches +45% y-o-y +24% y-o
Slide 4: 2021: A new chapter (I/II)
2021: A new chapter (I/II) During FY2021, IDH has transformed its business, rethinking its service offering and delivery capabilities, and setting the foundations for a new chapter of sustainable growth Test Offering and Reach Agility Delivery and Visibility Conventional Business Ramped up Ramped Up
Slide 5: 2021: A new chapter (II/II)
2021: A new chapter (II/II) During FY2021, IDH has transformed its business, rethinking its service offering and delivery capabilities, and setting the foundations for a new chapter of sustainable growth Improved Long-term Efficiency Relationships Decreased Turnaround Times and Improved Patient Sati
Slide 6: 2022 Outlook
2022 Outlook 1Q 2022 Trading Update Al-Borg Scan Nigeria Pakistan Net sales almost at par with last year Margins normalized Acquisition on track Continuous ramp up Conventional Offering Covid Offering to capitalise on the Consistent topline Long stop date A new wave of infections across venture’s gr
Slide 7: Important Notice: Reconciling IFRS and APM
Important Notice: Reconciling IFRS and APM During Q3 2021, management had reported the net sales generated from Biolab’s Detailed Adjustments Breakdown revenue sharing contracts (calculated as revenues minus concession fees and sales tax). EGP mn Q4 2021 FY 2021 The treatment of these contracts has
Slide 8: Results Overview: FY2019 vs FY2020 vs FY2021
Results Overview: FY2019 vs FY2020 vs FY2021 Net Sales* |M-EGP Gross Profit, GP%*** |M-EGP Adjusted EBITDA**, Adj. EBITDA%*** |M-EGP +13% +159% Growth in conventional net sales +168% 5,048 2,804 2,530 379 2,217 2,656 213 1,343 1,171 437 1,084 945 2,226 2,007 2,452 49% 51% 56% 42% 44% 50% FY2019 FY20
Slide 9: Revenue & EBITDA Bridges by Region
Revenue & EBITDA Bridges by Region IDH Revenue Bridge by Region | M-EGP, % Growth +90% 72.8% 17.3% -0.8% 0.7% IDH EBITDA Bridge by Region | M-EGP, EBITDA %, margin % +116% 99.5% 17.2% -0.6% -0. 01% *Net Sales is calculated as consolidated revenues minus concession fees paid by Biolab to QAIA and Aqa
Slide 10: IDH Covid-19 Contribution Analysis FY 2021
IDH Covid-19 Contribution Analysis FY 2021 FY 2020 FY 2021 Core Covid-19 Revenue (PCR & AG & Antibody) 437 (16%) 2.452 IDH FY 2021 Net Sales | Other Covid-19 Related Revenue (49%) 2.217 M-EGP, Y-o-Y 2.007 213 (44%) (76%) (8%) Conventional Revenue 379 (8%) 77% 23% PCR Net Sales: EGP 1,474 mn (36% of
Slide 11: Regional Performance: Subsidiaries in their Local Currency
Regional Performance: Subsidiaries in their Local Currency Jordan FY21 vs FY20 | mn JOD Sudan FY21 vs FY20 | mn SDG Nigeria* FY21 vs FY20 | mn NGN Jordan | mn JOD FY 2020 FY 2021 Growth Sudan | mn SDG FY 2020 FY 2021 Growth Nigeria | mn NGN FY 2020 FY 2021 Growth Revenue 18.5 39.4 113% Revenue 129 3
Slide 12: Al-Borg Scan (Egypt)
Al-Borg Scan (Egypt) In response to the fast-rising demand for Al-Borg Scan’s services, the Group launched two new branches in 2021 and another in March 2022, bringing the total number of branches to five, with plans to add two - three more by year-end 2022. Al Borg Scan offers a full range of radio
Slide 13: Echo-Lab (Nigeria)
Echo-Lab (Nigeria) In Nigeria, operations reported year-on-year revenue growth of 49% in FY 2021. Consistent revenue growth coupled with successful cost optimisation efforts see Echo-Lab aiming to turn EBITDA positive in early 2022. Monthly Revenue January 2020 to December 2021 | M-NGN* 134.1 136.6
Slide 14: Balance Sheet Analysis
Balance Sheet Analysis Gross Fixed Assets | M-EGP Consolidated Cash Balance | M-EGP Dividends |USD mn, Dividend Payout Ratio* | %, Dividends Per Share | USD 141% 113% 91% 89% 89% 87% 2,350 1,653 11 3% 70.0*** 1,247 26.4 28.0 29.1 877 21.0 24.0 31-Dec-20 31-Dec-21 31-Dec-20 31-Dec-21 2016 2017 2018 2
Slide 15: IDH – Q4 versus Q3 FY 2021
IDH – Q4 versus Q3 FY 2021 (EGP mn) (EGP mn) Normalized Net Sales* Q3 FY21 1,473 54% 790 EBITDA Q3 FY21 -13% -32% Q4 FY21 1,281 Q4 FY21 42% 537 Expenses (EGP mn) Total Raw Material Marketing & Advertising Accounting Fees Call Center EGP 297.2 million EGP 36.6 million EGP 17.7 million EGP 13.6 millio
Slide 16: IDH
INTEGRATED DIAGNOSTICS HOLDINGS IDH
Integrated Diagnostics Holdings — FY2021 Earnings Presentation on 6ix